To describe the utilization and compare quality outcomes of partial nephrectomy (PN) for cT1a, cT1b and cT2a renal masses using a large national database.
Introduction
Partial nephrectomy (PN) is the reference standard for clinical T1a renal masses [1] [2] [3] [4] . Emerging data suggest that select patients with larger renal masses (cT1b and cT2) may be successfully managed by PN with oncological equivalence to radical nephrectomy (RN) and improved renal functional preservation [5] [6] [7] [8] [9] [10] . Historically, PN has been underused [11] , even in the setting of strong indications such as preexisting chronic kidney disease (CKD) [12] . Indeed, while PN for cT1b tumours has evolved to become the standard treatment [1, 2] , the use of PN for cT2 tumours is controversial, with concern about the potential increased oncological risk associated with nephron-sparing procedures as well as a higher risk of postoperative morbidity [5, 6] . The aim of the present study was to use a large national oncological dataset to analyse trends in the use of PN and quality outcomes for cT1a, cT1b, and cT2a renal masses, and to examine the impact of the adoption of minimally invasive surgical techniques on quality outcomes.
Methods

Data Source
We conducted a retrospective cohort study using the deidentified National Cancer Database (NCDB). The NCDB, a hospital-based cancer registry administered by the American College of Surgeons and the American Cancer Society, captures information on the individual patient level, including clinical, demographic, treatment and overall survival information. The NCDB captures~70% of newly diagnosed cancer cases reported annually by >1 500 Commission on Cancer-accredited facilities [13] .
Study Population and Patient Selection
The study population included adults diagnosed with RCC between 2004 and 2013. International Classification of Diseases-O-3 histology codes were used to identify patients with RCC (8260, 8310, 8312, 8316, 8317, 8318) who underwent PN or RN (n = 221 197). We restricted our analysis to patients with tumours ≤10 cm, without evidence of venous tumour extension, nodal or metastatic disease (clinical stage cT1aN0M0, cT1bN0M0 and cT2aN0M0) [14] . We excluded patients with incomplete outcome data (preoperative tumour characteristics, pathological results, follow-up data) from the final analytical cohort. Complete selection criteria are shown in Fig. 1 .
Demographic variables included age at diagnosis, patient sex, race (black, white, other), and ethnicity (Hispanic, nonHispanic, other). Geographic region was categorized according to census regions as West, Midwest, East or South.
Median household income was separated by quartile based on census data linked to patient's area of residence zip code at time of diagnosis (adjusted for 2012 inflation). Health insurance status was categorized as private, Medicare (US government insurance for those aged ≥65 years), Medicaid (US government insurance for low-income persons), other or un-insured. The NCDB makes available Charlson comorbidity scores calculated based on pre-existing conditions at time of cancer diagnosis and coded as 0 vs 1 vs ≥2 [15] . Beginning in 2010, data regarding surgical approach (minimally invasive, i.e. robot-assisted or laparoscopic vs open) and conversion from minimally invasive to open surgery were explicitly recorded; these data were extracted for subset analysis. Facilities were grouped by overall hospital case volume; as per NCDB coding protocol, those with ≥500 newly diagnosed cases/year/site (academic facilities and comprehensive community centres) were considered 'high-volume', while those with <500 cases/year/site were considered 'low-volume' (community and integrated network centres).
Statistical Analysis
We sought to describe and quantify the use of PN in patients with cT1a, cT2b and cT2a renal masses, and to characterize how the use of PN changed over the study period. Furthermore, in the patients who underwent PN, we investigated the relationship between clinical tumour stage, demographics and peri-operative factors on quality outcomes [positive surgical margin (PSM) status and 30-day hospital readmission rate]. We chose to investigate PSMs and 30-day readmissions as key indicators of oncological precision and major morbidity [16] [17] [18] . We performed an additional subset analysis were assessed with chi-squared tests. We used multivariable logistic regression models to evaluate predictive factors for quality outcomes (PSM and 30-day readmission rates). All statistical tests performed were two-sided; P values <0.05 were taken to indicate statistical significance. Analyses were conducted using SAS, version 9.4 (SAS Institute Inc, Cary, NC, USA).
Results
Use of Partial Nephrectomy
Our analytical cohort included 43 749 patients with cT1a, cT1b or cT2a RCC undergoing PN. 
Surgical Outcomes after Partial Nephrectomy
Among patients who underwent PN, 34 796 (79.5%) had cT1a tumours, 8 040 (18.4%) had cT1b tumours and 913 (2.1%) had cT2a tumours. Patient characteristics and unadjusted analysis of the PN subset are shown in Table 1 . Patients in the cT1a subgroup were younger, a greater proportion were female and a greater proportion were white (all P < 0.05). The cT1a subgroup had a higher proportion of patients with a Charlson comorbidity score of 0 (fewer major comorbidities; P < 0.001). This unadjusted analysis showed no significant difference between proportion of patients in all clinical stage subgroups who had PSMs (cT1a, 6.9%; cT1b, 6.5%; cT2a, 6.2%; P = 0.33). The raw proportion of patients who required 30-day readmission was highest among those with cT1b tumours who underwent PN (5.1%; cT1a, 3.9%; cT2a, 4.4%; P < 0.001). Table 2 shows predictive factors in multivariable analysis for PSMs and 30-day hospital readmissions. Overall, 2 985 patients (6.8%) who underwent PN had PSMs. After adjusting for the impact of age, year of diagnosis, sex, race, comorbidities, facility volume and insurance status we found that the odds of PSMs after PN for cT1b tumours were significantly lower than after PN for cT1a tumours [odds ratio (OR) 0.90; P = 0.03]. There was no significant difference in the odds of PSMs after PN for cT2a tumours vs cT1a tumours (OR: 0.85; P = 0.25). Predictive factors for PSMs included increasing age (OR: 1.01; P < 0.001), later year of diagnosis (OR: 1.05; P < 0.001) and black race (OR: 1.13; P = 0.03). Overall, 1 821 patients (4.2%) who underwent PN were readmitted within 30 days. In a similarly adjusted analysis, there was an increased odds of 30-day readmission after PN for cT1b tumours compared with cT1a tumours (OR: 1.31; P < 0.001); there was no difference between cT2a and cT1a tumours (OR: 1.12; P = 0.5). Furthermore, higher comorbidity score (OR: 1.32; P = 0.001) and non-private insurance (Medicaid OR: 1.68, P < 0.001; Medicare OR: 1.21 P = 0.005; uninsured OR: 1.97, P < 0.001) were associated with increased odds of 30-day readmission. By contrast, later year of diagnosis was associated with decreased odds of readmission (OR: 0.96; P < 0.001).
Use of Minimally Invasive Approaches to Partial Nephrectomy: 2010-2013
We performed a subset analysis of PN for the period 2010-2013 to examine the effect of surgical approach on quality outcomes. Of the 27 504 PNs performed in 2010-2013, 40.4% were planned as open, 57.8% were planned and completed as minimally invasive (robotically or laparoscopically assisted) and 1.8% were converted intra-operatively from minimally invasive to open surgery. The majority of PNs for cT1a tumours were planned as minimally invasive (60.8%) compared with 48.3% for cT1b and 38.4% for cT2a tumours (P < 0.001). Figure 4 shows the utilization of minimally invasive PN in 2010-2013. The overall significant trend from 2010 to 2013 towards increased use of a minimally invasive approach was reflected among all subgroups [cT1a: 52.8-69.6% (P < 0.001); cT1b: 39.9-59.6% (P < 0.001); cT2a: 33.3-47.3% (P = 0.01)]. The proportion requiring intra-operative conversion ranged from 1.8% (cT1b) to 2.3% (cT2a), with 1.9% of cT1a tumours inbetween.
Surgical Outcomes after Partial Nephrectomy: 2010-2013
Complete characteristics and unadjusted analysis of the 2010-2013 PN subset are shown in Table 3 . On unadjusted analysis, there was no significant difference between the proportion of patients in each clinical stage who had PSMs (cT1a, 7.4%; cT1b, 7.1%; cT2a, 7.0%; P = 0.68), while 30-day readmission rates were highest in the cT1b group [5.2% compared with 4.3% for the cT2 and 3.7% for the cT1a group (P < 0.001)]. Table 4 shows the multivariable analysis of predictive factors for PSMs and 30-day hospital readmissions in the 2010-2013 PN cohort, with surgical approach (minimally invasive vs open) included as a variable. In this subset, 2012 patients (7.3%) had PSMs. Predictive factors for PSMs included older age (OR: 1.01; P < 0.001), minimally invasive approach (OR:
1.52; P < 0.001) and need for conversion (OR: 1.52; P = 0.01). A total of 1 108 patients (4.0%) were readmitted within 30 days. In a similarly adjusted analysis, predictive factors for readmission included lack of private insurance [uninsured, OR: 2.07 (P < 0.001); Medicaid, OR: 1.63 (P < 0.001); Medicare, OR: 1.23 (P < 0.001)], and undergoing intraoperative conversion from minimally invasive to open surgery (OR: 1.63; P = 0.009). 
Discussion
The present study is the first to focus on quality outcomes in addition to trends in the use of PN for cT1a, cT1b and cT2a masses, using a large national dataset. Our findings highlight increasing use of PN across clinical stage groups, accompanied by a time-related decrease in 30-day readmissions. We noted similar surgical quality for cT2a compared with cT1a/cT1b masses, which challenges the prevailing assumption that PN for cT2a mass is inherently associated with greater risk. Nonetheless the across-stage increase in PSMs associated with increasing adoption of the minimally invasive technique suggests a quality-of-care concern that requires further attention and reductive measures.
Promulgation of the clinical T1 renal mass AUA guidelines in 2009 has changed the trend in the use of PN over time [19] . Our previous analysis using the Nationwide Inpatient Sample database (which contains a survey of~20% of all US community hospitals) from 2007 to 2011 showed that, before the guidelines, 28.9% of patients with renal tumours underwent PN, compared with 35.3% after promulgation of the guidelines (P < 0.001). Statistically, after the publication of the AUA guidelines, patients had a 24% increased odds of undergoing a PN (OR: 1.242) [20] . Our findings were similar to those of Bjurlin et al. [21] who analysed the Nationwide Inpatient Sample for the period 2007-2010 and noted that publication of AUA Guidelines was an independent predictor for PN [21] . Nonetheless, both reports showed that, despite release of the guidelines, PN continued to be underused even for patients with a strong indication, such as those with preexisting CKD [20, 21] , suggesting that the increase in PN use in the short-term after release of the guidelines has been mostly for elective indications, and that significant barriers to the use of nephron-sparing techniques continue to exist, especially in at-risk patients such as those with CKD [11, 12] . Other reports have examined the impact of adoption on minimally invasive PN on surgical quality and the overall use of PN. Liu et al. [22] queried the National Surgical Quality Improvement Program database for the period 2005-2011 and noted that, while overall complication rates decreased for all approaches of PN (open and minimally invasive), minimally invasive PN was associated with lower transfusion, major complication and peri-operative mortality rates [22] . Additionally, Patel et al. [23] , using the Maryland Health Services Cost Review Commission database, showed that the increase in use of PN was predicted by adoption of robotassisted PN (OR: 9.67; P < 0.001), irrespective of practice setting and higher hospital volume [23] , suggesting that increased experience with the robotic platform may facilitate broader utilization of PN which may overcome the relative under-utilization of this approach in community practice settings [24] .
Our findings are similar to those of other studies in demonstrating an increase in the use of PN for cT1a, cT1b and cT2a masses overall [10, 25] . Furthermore, the present study is the first to show a rise in the use of a minimally invasive PN approach for cT2a tumours, which parallels reported trends for increasing use of minimally invasive PN for cT1a and cT1b masses [25] . Although this is encouraging, any enthusiasm generated by these findings must be tempered by the increased risk of PSMs found by both the present authors and Maurice et al. [26] . Indeed, while we noted no difference in PSM rates among PN-treated cT1a, cT1b and cT2a masses, there was an increase in PSMs overall, attributable to the increased use of minimally invasive approaches over time. As such, higher clinical tumour stage was not the main driver in terms of risk of PSMs, but rather it was the increased adoption of minimally invasive approaches. These findings are similar to those of Maurice et al. [26] , who analysed the NCDB for the period 2003-2011 to evaluate the use of PN for high-risk disease [disease with ≥1 adverse pathological feature (pT3 stage), high grade or unfavourable histology] and the PSM rates after PN for highrisk disease, and noted that PSMs increased over time (P < 0.01). Furthermore, they also noted that community hospital type (OR: 1.53; P < 0.01) and robot-assisted approach (2010-2011, OR: 1.44; P = 0.02) were associated with PSMs in the setting of adverse pathological features [26] . Taken together, the present findings and those of Maurice et al. suggest that increased use of PN attributable to increased adoption of minimally invasive techniques may not be an unbridled blessing, and that significant gaps in quality of care exist which need to be addressed. Based on the present findings, we stress the importance of patient selection for minimally invasive PN in particular, with stringent emphasis on complete tumour resection and gross intra-operative pathological assessment, with attainment of negative margins as a matter of oncological principle [1, 27] .
We used 30-day readmission rate, a metric frequently used as a surrogate for quality of care in both urological and nonurological procedures [18] . We noted increasing patient comorbidity, cT1b clinical tumour stage, minimally invasive conversion to open surgery, and non-private insurance status (Medicaid, Medicare and uninsured) to be predictive factors for readmission, while later year of diagnosis was associated with decreased readmission. Insurance status as a surrogate of socio-economic status is a well-documented risk factor for hospital readmissions after a variety of high-risk medical admissions and surgical procedures [28, 29] . Conversion to open surgery from a minimally invasive approach has been associated with increased risk of readmission and adverse outcomes in patients undergoing colectomy [30] . Although increasing tumour size has been shown to be correlated with readmission rates after PN in single-centre analyses [31] and analyses confined to cT1a tumours [32] , this was not confirmed by the present analysis. Increased risk of readmission for cT1b tumours but not for cT2a compared with cT1a tumours may be attributable to more stringent patient selection for larger (cT2a) tumours, which may be reflected in the lower rates of PN utilization for cT2a tumours and greater use of PN for cT1b tumours. To our knowledge, this is the first demonstration of these predictive factors in a national PN cohort. Our findings highlight a need to improve quality of care by implementing improved patient selection strategies for minimally invasive surgery preoperatively and by identification of patients at risk for readmission because of comorbidity and socio-economic factors, and to implement closer follow-up and support after discharge for such patients.
The limitations of the present study are mainly related to features of the NCDB and the study's retrospective design. The NCDB includes readmission data 30 days postoperatively, and does not include specific peri-operative data related to the surgery itself or immediate postoperative complications (e.g. estimated blood loss, ischaemia time, urine leak). While 30-day readmission rate is a composite marker of global 'morbidity' postoperatively, it may reflect the complexity/comorbidity of the patient population rather than surgical technical factors. As in all retrospective studies, we were unable to control for any surgeon preference that may have led to a selection bias among the PN cohort. The NCDB does not contain data on absolute and relative indications for PN, such as presence of a solitary kidney or diabetes mellitus. Furthermore, the treatment decision for PN vs RN is most often made preoperatively based on imaging findings demonstrating suspicion for RCC; therefore, a proportion of benign cortical tumours whose outcomes with respect to margins and 30-day readmission rates would not have been available for analysis in the NCDB and which may have impacted findings, especially in the cT1a cohort where up to 20-30% of cortical tumours are benign in histology. Despite these limitations, given the robust sample size and complete demographic and staging information, we were able to thoroughly describe the use of PN and provide further insight into the treatments of patients with larger renal tumours in the USA. Our findings suggest that quality outcomes for PN in cT1a, cT1b and cT2a disease are similar and that tumour size itself should not be a contraindication to PN, especially if nephron preservation is imperative or thought to be of particular advantage to the patient. Furthermore, the present findings raise quality-of-care concerns with respect to PSMs and readmission; these concerns could lead to implementation of meaningful reductive strategies. Our findings should be considered as hypothesis-forming and should ideally be confirmed by randomized and prospective clinical trials of RN and RN for cT1b and cT2a renal masses [33] .
In conclusion, the use of PN for cT1a, cT1b and cT2a renal tumours has increased over time, and has been accompanied by a decrease in 30-day readmission rates as well as an increase in PSM rates, which is driven by increasing use of minimally invasive techniques. This latter trend may represent an oncological quality-of-care concern. Further investigation is required to delineate the impact of these trends and to inform quality improvement strategies.
